Skip to main content

Table 1 Genotype and allele distribution of CD226 rs763361 (chr:18, 65,682,622 bp), rs34794968 (chr:18; 65,682,006 bp), rs727088 (chr:18, 65,681,419 bp) genetic variants and pooled analysis.

From: A multicenter study confirms CD226gene association with systemic sclerosis-related pulmonary fibrosis

  

Genotype, N (%)

 

Allele test

SNP

Subgroup (N)

1/1

1/2

2/2

MAF (%)

P MH

P FDR_BH

OR [CI 95%]

P BD

rs763361

Controls (n = 3811)

906 (23.77)

1841 (48.31)

1064 (27.92)

47.93

    
 

SSc (n = 2023)

480 (23.73)

990 (48.94)

553 (27.34)

48.2

0.56

0.73

1.02 [0.95-1.10]

0.56

 

lcSSc (n = 1397)

332 (23.77)

681 (48.75)

384 (27.49)

48.14

0.64

0.95

1.02 [0.94-1.11]

0.8

 

dcSSc (n = 626)

148 (23.64)

309 (49.36)

169 (27.00)

48.32

0.6

0.94

1.03 [0.92-1.17]

0.14

 

ACA+ (n = 797)

176 (22.08)

396 (49.69)

225 (28.23)

46.93

0.68

0.68

0.98 [0.88-1.09]

0.85

 

ATA+ (n = 503)

133 (26.44)

239 (47.51)

131 (26.04)

50.2

0.22

0.28

1.09 [0.95-1.24]

0.63

 

Fib+ (n = 729)

176 (24.14)

359 (49.25)

194 (26.61)

48.77

0.48

0.58

1.04 [0.93-1.17]

0.5

rs34794968

Controls (n = 3858)

669 (17.34)

1842 (47.74)

1347 (34.91)

41.21

    
 

SSc (n = 2060)

348 (16.89)

978 (47.48)

734 (35.63)

40.63

0.73

0.73

0.99 [0.91-1.07]

0.37

 

lcSSc (n = 1422)

234 (16.46)

685 (48.17)

503 (35.37)

40.54

0.74

0.95

0.99 [0.90-1.08]

0.71

 

dcSSc (n = 638)

114 (17.87)

293 (45.92)

231 (36.21)

40.83

0.94

0.94

1.00 [0.88-1.12]

0.05

 

ACA+ (n = 816)

129 (15.81)

390 (47.79)

297 (36.40)

39.71

0.35

0.68

0.95 [0.85-1.06]

0.6

 

ATA+ (n = 518)

100 (19.31)

249 (48.07)

169 (32.63)

43.34

0.28

0.28

1.08 [0.94-1.23]

0.38

 

Fib+ (n = 755)

122 (16.16)

362 (47.95)

271 (35.89)

40.13

0.58

0.58

0.97 [0.87-1.09]

0.44

rs727088

Controls (n = 3815)

917 (24.04)

1869 (48.99)

1029 (26.97)

48.53

    
 

SSc (n = 2042)

489 (23.95)

1014 (49.66)

539 (26.40)

48.78

0.59

0.73

1.02 [0.95-1.10]

0.86

 

lcSSc (n = 1409)

336 (23.85)

702 (49.82)

371 (26.33)

48.76

0.63

0.95

1.02 [0.94-1.11]

0.66

 

dcSSc (n = 633)

153 (24.17)

312 (49.29)

168 (26.54)

48.82

0.71

0.94

1.02 [0.91-1.15]

0.26

 

ACA+ (n = 814)

178 (21.87)

414 (50.86)

222 (27.27)

47.3

0.54

0.68

0.97 [0.87-1.08]

0.56

 

ATA+ (n = 514)

138 (26.85)

250 (48.64)

126 (24.51)

51.17

0.14

0.28

1.10 [0.97-1.26]

0.61

 

Fib+ (n = 739)

185 (25.03)

363 (49.12)

191 (25.85)

49.59

0.4

0.58

1.05 [0.94-1.17]

0.86

  1. Controls are used as reference for all comparisons. ACA, anti-centromere antibodies; ATA, anti-topoisomerase antibodies; 95% CI, 95% confidence interval; dcSSc, diffuse cutaneous systemic sclerosis; Fib+, lung fibrosis positive SSc patients; lcSSc, limited cutaneous systemic sclerosis; MAF, minor allele frequency; NS, not significant; OR, odds ratio; PBD, Breslow-Day homogeneity test p-value; P FDR_BH, corrected P-value using Benjamini and Hochberg false discovery rate; PMH, allelic Mantel-Haenszel fixed effects model P-value; SSc, systemic sclerosis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us